Centocor, Inc.

Johns Hopkins University

University of Oklahoma

Leon A Epps

George A Heavner

Marian Kruszynski

Rodger P McEver

Douglas James Riexinger

Robert Francis Dannals

Miljenko Mervic

Hugh D Burns

Alfred V Kramer

Jian-Guo Geng

Susan E Zemyan

Peptides derived from three regions of the lectin domain of GMP-140 (P-selectin) and the related selectins, ELAM-1 (E-selectin) and the lymphocyte homing receptor (L-selectin), have been found to inhibit neutrophil adhesion to GMP-140. These and additional peptides have been synthesized, having as their core region portions of the 74-76 amino acid sequence of GMP-140, with residue 1 defined as the N-terminus of the mature protein after the cleavage of the signal peptide. Examples demonstrate the inhibition of the binding of neutrophils to GMP-140 of peptides in concentrations ranging from 30 to 1500 .mu.mol. It has been found that alterations within the core sequence, as well as N-terminal and C-terminal flanking regions, do not result in loss of biological activity. The peptides are useful as diagnostics and, in combination with a suitable pharmaceutical carrier, for clinical applications in the modulation or inhibition of coagulation processes or inflammatory processes.

Peptide inhibitors of inflammation mediated by selectins

The present invention provides novel peptides derived from portions of the sequence of amino acids 42-48 of P-selectin. The invention also provides pharmaceutical compositions comprising the peptides of the invention, and diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention.

Peptide inhibitors of leukocyte adhesion

The present invention provides novel peptides derived from portions of the sequence of amino acids 23-26 and 27-30 of P-selectin. The invention also provides pharmaceutical compositions comprising the peptides of the invention, and diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention. The peptides of this invention can be used in the modulation or inhibition of coagulation processes or inflammatory processes.

Peptide inhibitors of selectin binding

The present invention relates to coordination compounds of technetium-99m and chelating agents (ligands) for synthesizing them. The technetium compounds are useful as diagnostic brain imaging radiopharmaceuticals.

Brain imaging radiopharmaceuticals

Growing community of inventors

Baltimore, MD, United States of America

Leon A Epps